We use cookies to help provide you with the best possible online experience. Learn more

Press releases

RayStation selected for major new proton therapy center in China

RayStation will be the treatment planning system for a new proton center in Zhuozhou, Northern China, situated close to Beijing. Around 2,000 patients per year will be treated at Zhuozhou, which will be one of the biggest proton centers in the world. The center will be equipped with IBA’s Proteus®PLUS multi-room system; the setup includes five treatment rooms, four isocentric-gantry treatment rooms and a fixed-beam treatment room.

The RayStation order, comprising eight clinical licenses, covers a range of advanced functionality, such as Monte Carlo dose calculation, robust optimization, proton PBS and DS planning, and fallback planning. Additional planning features for photon therapy will be included, such as 3D-CRT, IMRT, VMAT photon planning, and the system will also be used as a platform for research. Deployment of the treatment planning system is set to begin from August and clinical use will commence subject to regulatory clearance. 

Olivier Legrain, CEO of IBA, says: “Our collaboration with RaySearch has enabled us to deliver a comprehensive solution that will give patients in Zhuozhou and the surrounding area access to the most advanced radiation therapy treatment available. IBA Proton Therapy systems, combined with RayStation, offer advanced functionality and unmatched usability to extend treatment possibilities.”

Johan Löf, CEO of RaySearch, says: “It is very exciting to be part of this project to establish the first large proton center in a hospital environment in China. Proton therapy is taking off in China, and we aim to be at the forefront of developments. Together with IBA, we are able to deliver a complete platform that will optimize workflows and enable precise and personalized treatment.”

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single-room systems. IBA also has a radiation dosimetry business and develops particle accelerators for medical and industrial applications. Headquartered in Belgium and employing more than 1,300 people worldwide, IBA has installed systems around the world. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

About RayStation
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®*, which comprises a new product area for RaySearch, and which will be launched in 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.
* Subject to regulatory clearance in some markets

More information about RaySearch is available at www.raysearchlabs.com 

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00